Suppr超能文献

重症监护病房中用于血管舒张性休克的血管活性药物。

Vasoactive drugs for vasodilatory shock in ICU.

作者信息

Holmes Cheryl L, Walley Keith R

机构信息

Department of Medicine, Kelowna General Hospital, University of British Columbia, Kelowna, British Columbia, Canada.

出版信息

Curr Opin Crit Care. 2009 Oct;15(5):398-402. doi: 10.1097/MCC.0b013e32832e96ef.

Abstract

PURPOSE OF REVIEW

Vasoactive drugs are the mainstay of hemodynamic management of vasodilatory shock when fluids fail to restore adequate tissue perfusion. In this review, studies published during the past year that increase our understanding of the use of vasoactive drugs in the ICU are discussed.

RECENT FINDINGS

The Vasopressin and Septic Shock Trial did not find a difference between low-dose vasopressin and norepinephrine vs. norepinephrine alone in the hemodynamic support of septic shock, suggesting that either approach is reasonable. However, vasopressin may be beneficial in the less severe septic shock subgroup. In this study, patients who were also treated with corticosteroids, vasopressin, compared with norepinephrine, were associated with significantly decreased mortality. Epinephrine, phenylephrine and terlipressin can be used safely in the ICU setting as first-line therapy for septic shock. The incidence of global left ventricular hypokinesia in patients with septic shock is 60%, much higher than previously described. Although dobutamine remains the gold standard therapy for septic myocardial depression, combined milrinone and metoprolol therapy may be an effective alternative therapy.

SUMMARY

Current evidence does not support a clear recommendation of one vasopressor over another; indeed norepinephrine, vasopressin, terlipressin, phenylephrine and epinephrine may be used safely with similar survival outcomes.

摘要

综述目的

当液体复苏不能恢复足够的组织灌注时,血管活性药物是血管扩张性休克血流动力学管理的主要手段。在本综述中,将讨论过去一年发表的、能增进我们对重症监护病房(ICU)中血管活性药物使用理解的研究。

最新发现

血管加压素与脓毒性休克试验并未发现,在脓毒性休克的血流动力学支持方面,低剂量血管加压素与去甲肾上腺素联合用药和单独使用去甲肾上腺素之间存在差异,这表明两种方法都是合理的。然而,血管加压素可能对病情较轻的脓毒性休克亚组有益。在这项研究中,同时接受皮质类固醇和血管加压素治疗的患者与接受去甲肾上腺素治疗的患者相比,死亡率显著降低。肾上腺素、去氧肾上腺素和特利加压素可在ICU环境中安全地用作脓毒性休克的一线治疗药物。脓毒性休克患者中全球左心室运动功能减退的发生率为60%,远高于先前描述的水平。尽管多巴酚丁胺仍然是脓毒性心肌抑制的金标准治疗药物,但米力农和美托洛尔联合治疗可能是一种有效的替代治疗方法。

总结

目前的证据不支持明确推荐一种血管升压药优于另一种;事实上,去甲肾上腺素、血管加压素、特利加压素、去氧肾上腺素和肾上腺素可以安全使用,且生存结果相似。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验